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Abstract
Background: Inflammatory bowel disease (IBD) is hypothesized to result from stimulation of immune responses against
resident intestinal bacteria within a genetically susceptible host. Mast cells may play a critical role in IBD pathogenesis, since
they are typically located just beneath the intestinal mucosal barrier and can be activated by bacterial antigens.
Methodology/Principal Findings: This study investigated effects of mast cells on inflammation and associated neoplasia in
IBD-susceptible interleukin (IL)-10-deficient mice with and without mast cells. IL-10-deficient mast cells produced more pro-
inflammatory cytokines in vitro both constitutively and when triggered, compared with wild type mast cells. However
despite this enhanced in vitro response, mast cell-sufficient Il10
2/2 mice actually had decreased cecal expression of tumor
necrosis factor (TNF) and interferon (IFN)-c mRNA, suggesting that mast cells regulate inflammation in vivo. Mast cell
deficiency predisposed Il10
2/2 mice to the development of spontaneous colitis and resulted in increased intestinal
permeability in vivo that preceded the development of colon inflammation. However, mast cell deficiency did not affect the
severity of IBD triggered by non-steroidal anti-inflammatory agents (NSAID) exposure or helicobacter infection that also
affect intestinal permeability.
Conclusions/Significance: Mast cells thus appear to have a primarily protective role within the colonic microenvironment
by enhancing the efficacy of the mucosal barrier. In addition, although mast cells were previously implicated in progression
of sporadic colon cancers, mast cells did not affect the incidence or severity of colonic neoplasia in this inflammation-
associated model.
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Introduction
Inflammatory bowel disease (IBD) is characterized by aberrant
immune responses against microorganisms that are present in the
intestine. Debilitating clinical symptoms of pain and diarrhea
result from intestinal mucosal damage that is driven by the
continuous activation of the mucosal immune system by enteric
bacteria. A variety of genetic, microbial, and environmental
factors have been identified that increase susceptibility to IBD in
both animal models and humans. Based on this data, we have
proposed that the development of IBD requires three factors [1].
First, bacterial antigens and adjuvants must be present within the
intestine. This factor is not easily modifiable, since potentially
colitogenic bacterial antigens and adjuvants are present within the
intestine of all humans and all mice that are not kept in germ-free
facilities. Second, the mucosal barrier must be defective so that the
bacterial antigens and adjuvants present within the intestine can
come in contact with the innate and adaptive immune cells to
generate responses. And third, the host must have a defect in
immune regulation that allows induction of sustained immune
responses against these antigens. This three-factor model can
potentially explain how the known susceptibility alleles and IBD-
related triggers in existing murine models result in the develop-
ment of chronic colitis. The model also predicts that colitis can
potentially be prevented or treated by interventions that favor
maintenance of appropriate immune regulation and/or enhance-
ment of mucosal barrier function.
Most of the currently used IBD treatments target the immune
regulatory pathways, but resulting immunosuppression can
increase patient risk for developing opportunistic infections and/
or treatment-related lymphomas. Mechanisms that govern the
barrier function of the intestinal mucosa are thus of great interest
to identify potential targets for novel IBD therapies that can add or
synergize with existing therapies. A number of murine models of
intestinal inflammation have been established [1,2]. One very
commonly used model uses mice deficient in interleukin (IL)-10.
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chronic enterocolitis with loss of tolerance to bacterial stimuli
when triggered by environmental exposures that decrease mucosal
barrier function [3,4,5,6].
Mast cells are innate immune cells that can potentially
contribute to IBD through their pro- inflammatory activity and/
or effects on immunoregulation. Their pattern recognition
molecules allow them to readily recognize and rapidly respond
to bacteria that breach the epithelium [7]. Upon activation, mast
cells can immediately release large amounts of pro-inflammatory
cytokines that are contained in pre-formed granules [8] and can
continue to synthesize and release a wide array of pro-
inflammatory mediators de novo. Mast cells thus rapidly and
selectively produce appropriate mediators that enhance effector-
cell recruitment and complement other effector components of the
immune system [9]. For example, mast cell-derived mediators can
contribute to colitis severity by enhancing neutrophil influx and
thus perpetuating ongoing inflammation. However mast cells have
also been documented to have anti-inflammatory or immunosup-
pressive functions, such that they can serve to either enhance or to
limit innate or adaptive immune responses, depending on the
context [10].
Mast cells are physically located adjacent to the intestinal
epithelium, so their activation may also affect the function of the
mucosal barrier. The presence of mast cells or the mast cell-
produced proteinase Mcpt4 (chymase) was recently shown to
enhance the permeability of jejunal segments studied ex vivo [8].
The same study showed that mast cell-deficient Kit
W-sh/W-sh (sash)
mice have changes in small intestinal architecture, including
increased crypt depth, decreased migration of epithelial cells up
the villus, and decreased expression of the tight junction protein
claudin-3 compared to wild type mice [8]. Claudin-3 is an
important sealing protein and its loss from colon tissue has been
correlated with lack of tight junction integrity [11]. Mast cells have
also been shown to mediate increased intestinal permeability
caused by exposure to stress neuropeptides (e.g. corticotropin-
releasing factor or sauvagine) in vitro [12]. Several studies have
shown increased numbers of mast cells or increased release of mast
cell mediators from actively inflamed colon of IBD patients
compared with non-inflamed colon or normal controls
[13,14,15,16], suggesting a potential role for mast cells in the
pathogenesis of IBD. However, specific in vivo data relating to
mechanisms by which mast cells may influence IBD pathogenesis
remains limited.
In view of the the well known role of mast cells in exacerbating
inflammatory diseases such as arthritis, allergy, and asthma
[17,18,19] and the potential of mast cells to contribute to one or
more of the three factors that affect development of IBD, we
hypothesized that mast cells might play a prominent role in the
pathogenesis of IBD. We used a well-established model of IBD,
based on IL-10-deficient mice with and without added mast cell
deficiency to test this hypothesis.
Results
Mediator response is elevated in Il10
2/2 mast cells, but
absence of mast cells does not affect the severity of IBD
triggered by piroxicam in Il10
2/2 mice
The purpose of these studies was to determine the role of mast
cells in the pathogenesis of IBD. Il10
2/2 mice were used, since they
are highly susceptible to developing IBD when subjected to
conditions that enhance mucosal permeability. Since IL-10 can
also directly affect the function of immune cells including mast cells
[20], bone marrow-derived mast cells (BMMC) from wild-type
(WT) and Il10
2/2 mice were first compared to determine how IL-
10 deficiency affected the ability of BMMC to produce other
inflammatory mediators. Similar mast cell survival and %
degranulation in vitro were observed for WT vs. Il10
2/2 BMMC
after the treatment with IgE + cross-linking with anti-IgE. Exposure
to enteric bacteria (cecal contents) did not cause significant
degranulation of either wild type or Il10
2/2 mast cells and also
did not affect mast cell survival (data not shown). However, Il10
2/2
BMMC produced higher baseline levels of IL-6, MCP-1, and MIP-
1a in the absence of stimulation (buffer-treated cells) than did WT
BMMC (Figure 1). Levels of IL-6 and MCP-1 secretion following
IgE-induced degranulation were further increased in Il10
2/2
BMMC compared with WT BMMC (Figure 1). Exposure of
BMMC to enteric bacteria (cecal contents) triggered a pattern of
cytokine production distinct from that triggered by IgE stimulation,
with increased production of tumor necrosis factor (TNF) by
Il10
2/2 compared with WT BMMC (p,0.05), but decreased or
unchanged production of MCP-1, IL-6, and MIP-1a (Figure 1).
The increased baseline and stimulated production of pro-inflam-
matory cytokines by Il10
2/2 BMMC to both classic (e.g. IgE) and
IBD-relevant (e.g. enteric bacteria) activation stimuli in vitro
suggested that Il10
2/2 mast cells might be particularly potent in
stimulating inflammatory reactions in the gut following breakdown
of the mucosal barrier in vivo.
Exposure to the non-steroidal anti-inflammatory agent (NSAID)
piroxicam uniformly triggers the development of IBD in Il10
2/2
mice by enhancing apoptosis of mucosal epithelial cells, resulting
in barrier breakdown that massively exposes immune cells in the
lamina propria to bacterial antigens [5]. Mice variously deficient
in IL-10 and mast cells received 200 ppm piroxicam for 7 days
and then were observed for 16 additional days prior to assessment
of colon inflammation. Wild type mice did not develop chronic
colitis when exposed to piroxicam (mean histologic scores 6 SEM
=762; Figure 2). Mast cell-deficient sash mice also did not
develop colitis following piroxicam exposure, either with or
without reconstitution with WT BMMC (Figure 2). As reported
previously [5], IL-10-deficient mice developed moderate to severe
colitis when exposed to piroxicam (mean histologic scores 6 SEM
=3065; Figure 2). Il10
2/2 mice with mast cell deficiency due to
the Kit
W-sh/Kit
W-sh mutation (DKO mice), DKO mice reconstitut-
ed with WT BMMC, and DKO mice reconstituted with Il10
2/2
BMMC also developed moderate to severe colitis when exposed to
piroxicam, with severity that statistically did not differ from that
seen in mast cell-sufficient Il10
2/2 mice (p=0.14, 0.34, and 0.93,
respectively; Figure 2). Thus, even though Il10
2/2 mast cells
produce elevated levels of inflammatory mediators when stimu-
lated in vitro, the absence of mast cells does not affect the severity of
IBD triggered by exposure of Il10
2/2 mice to the mucosal barrier-
damaging NSAID piroxicam.
Mast cells modulate production of pro-inflammatory
mediators in vivo, but absence of mast cells does not
affect the severity of helicobacter-triggered IBD in
Il10
2/2 mice
In vivo activation responses of mast cells may differ from their
responses in vitro due to the complexities of the in vivo colonic
microenvironment. To address this issue, we determined the effect
of mast cells on the inflammatory milieu in IBD-susceptible and
control mice with mucosal barrier compromise due to helicobacter
infection. Colon tissues from Il10
2/2, DKO, sash, and TNF-
deficient mice with and without co-infection by H. typhlonius and H.
rodentium were analyzed for inflammation severity and for the
production of selected cytokines by real time reverse transcriptase
Mast Cells and IBD
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time point, Il10
2/2 and DKO mice have severe chronic colitis,
while Tnf
2/2 and mast cell-deficient sash mice do not (Figure 3).
DKO mice had significantly increased production of mRNA
encoding TNF and interferon (IFN)-c, with strong trends toward
increased IL-4 and IL-12/23p40 compared with mast cell-
sufficient Il10
2/2 mice (Figure 4). Elevated levels of IL-4 were
also seen in sash mice singly deficient in mast cells and in TNF-
deficient mice that do not develop colitis under these conditions,
compared with Il10
2/2 mice that develop severe colitis (Figure 4).
Thus, tissue from DKO mice with colitis showed increased
production of pro-inflammatory cytokines compared with mice
singly deficient in IL-10, mast cells, or TNF. This demonstrates
that mast cells play a role in down-regulating production of pro-
inflammatory cytokines within the inflamed colon, at this relatively
early time point in the course of chronic colitis.
To determine how mast cells affected the long-term severity
of IBD in helicobacter-infected mice that had sustained mucosal
barrier dysfunction, Il10
2/2 and DKO mice were infected with
H. rodentium and H. typhlonius and monitored for up to 27 wks
post-infection. Infected Il10
2/2 and DKO mice both demon-
strated severe colitis that was slightly increased in the absence of
mast cells (mean histologic score =4361i nIl10
2/2 mice vs.
4862i nD K Om i c e ;p=0.03) (Figure 5A). However, this slight
difference in colitis severity did not translate into a difference in
survival based on presence or absence of mast cells (p=0.29;
Figure 5B).
Mast cells do not affect inflammation-associated colonic
neoplasia in helicobacter-infected Il10
2/2 mice
Colonic inflammation has previously been shown to predispose
to the development of malignancy, both in humans and in murine
models of IBD [6,21]. Mast cells have also been shown to affect
the incidence and severity of neoplasia in models of sporadic colon
cancers [22,23]. Therefore, the effect of mast cells on inflamma-
tion-associated neoplasia was also investigated in Il10
2/2 mice
with colitis triggered by helicobacter infection. Sixty three percent
of Il10
2/2 mice (n=24) developed colorectal neoplasia by 1861
weeks after IBD triggering, with an average of 362 neoplastic
lesions per mouse (range=1–6) (Figure 6A and B). Similarly, 62%
(n=21) of DKO mice had colorectal neoplasia 1761 weeks after
IBD triggering, with an average of 261 neoplastic lesions per
mouse (range=1–6) (Figure 6C and D). Half of these neoplastic
lesions were invasive at the time of detection in both groups. Thus
mast cells do not affect the incidence of inflammation-associated
neoplasia in Il10
2/2 mice with severe long-standing compromise
of the mucosal barrier due to helicobacter infection.
Figure 1. BMMC cytokine production after stimulation with IgE or enteric bacteria. BMMC were stimulated for 4 hrs, then media was
harvested for cytokine analysis via Luminex bead-based fluorescent immunoassays. Il10
2/2 BMMC make more IL-6, MCP-1, and MIP-1a constitutively
(buffer treatment) and following IgE stimulation than WT BMMC (p,0.05). Exposure to enteric bacteria in cecal contents triggers a different pattern of
cytokine expression, with higher TNF production by Il10
2/2 vs. WT BMMC. Data shown is the mean 6 SEM for 3–5 independent experiments.
* indicates p#0.05 vs. WT.
doi:10.1371/journal.pone.0012220.g001
Mast Cells and IBD
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development of IBD in Il10
2/2 mice
Since we did not see any contributory role for mast cells in
actively induced inflammatory responses in gut of Il10
2/2 mice,
we investigated whether mast cells had a role in the spontaneous
development of IBD in Il10
2/2 vs. DKO mice. All mice were
documented to remain free of helicobacter infection throughout
the study. Whereas most mast cell-sufficient Il10
2/2 mice did not
develop colitis by 9 months of age (mean histologic score 6 SEM
=1362), most DKO mice developed at least moderate colitis
(mean 6 SEM histologic score =2764) (Figure 7). These DKO
mice were significantly younger (3162 wks; range =25–38 wks;
n=10) than the Il10
2/2 mice studied (3661 wks; range 34–
36 wks; n=15; p=0.02) due to more frequent occurrence of rectal
prolapse (an indicator of severe IBD) in DKO mice that led to
euthanasia for humane reasons prior to the planned study
endpoint. Overall, these results demonstrate that mast cells protect
Il10
2/2 mice against the development of spontaneous colitis.
Mast cells enhance epithelial barrier function
Il10
2/2 mice have defects in immune regulation due to their
genetic deficiency of IL-10 and their intestines contain potentially
colitogenic antigens and adjuvants derived from their commensal
intestinal microbiota. The three factor model presented earlier
thus predicts that colitis will develop when the mucosal barrier is
compromised, a prediction supported by the ability of NSAIDs
and helicobacter infection to trigger colitis in these mice. Our
finding that absence of mast cells predisposed to spontaneous
development of IBD in Il10
2/2 mice suggested that absence of
mast cells might also decrease the effectiveness of the mucosal
barrier.
A quantitative assessment of barrier function was performed to
determine the effect of mast cells on intestinal permeability. Phenol
red dye was administered orally to Il10
2/2 vs. DKO mice in vivo
and the amount of dye recovered in urine was measured as an
indicator of intestinal paracellular permeability. DKO mice
exhibited higher permeability as indicated by increased dye
recovery (Figure 8B) compared to Il10
2/2 mice (Figure 8A;
p=0.02). Histologic scores indicated minimal to no inflammation
in the animals tested (mean histologic score 6 SEM=761 (n=33)
for DKO and 1563 (n=18) for Il10
2/2 mice). The increased
intestinal permeability of DKO mice was due to the Kit
W-sh
mutation that results in absence of mast cells, since it was also seen
in sash mice that lacked mast cells, but were wild type with respect
to IL-10 expression (Figure 8C). Taken together, these studies
indicate that mice that lack mast cells have increased intestinal
permeability. Furthermore, the data clearly show that the
decreased barrier integrity observed in DKO relative to Il10
2/2
mice occurs prior to, rather than in response to, the development
of colon inflammation.
Discussion
Although mast cells are best known for their pathogenic over-
responses in immune-mediated diseases such as allergy and
asthma, their protective role in innate immune responses is
underscored by high susceptibility of mice deficient in mast cells to
fatal infections with enteric bacteria [24,25]. Mast cells aid the
development of antigen-specific cellular and humoral adaptive
immune responses by stimulating lymph node swelling and
sequestration [26]. The data presented here suggest that mast
cells also enhance intestinal mucosal barrier function in vivo and
can protect against spontaneous development of IBD in suscep-
tible mouse strains.
Intestinal epithelial barrier function is regulated by epithelial
cells, innate and adaptive immunity, and the enteric nervous
system and dysregulation of any of these alters the barrier [27].
Several mast cell-derived mediators, including histamine, seroto-
nin, arachidonic acid, and mast cell proteinases have been shown
to affect intestinal epithelial function, including ion channel
conductance and activation/inhibition of secretion of electrolytes
and mucus [8,27,28]. Our results show that mast cell-deficient sash
and DKO mice had increased the baseline paracellular perme-
ability of the intestine in vivo, independent of IL-10 status (Figure 8).
Figure 2. Mast cells do not affect the severity of colitis
triggered by piroxicam. Mice of the indicated genotypes 6
reconstitution with WT or Il10
2/2 BMMC received 200 ppm piroxicam
67 days to trigger the onset of colitis. Tissue was harvested for
histologic analysis 16 d later. WT or sash mice 6 reconstitution with WT
BMMC did not develop colitis in this study. Mice deficient in IL-10
uniformly developed colitis, however the presence or absence of mast
cells and whether or not the mast cells could produce IL-10 did not
affect the severity of inflammation.
doi:10.1371/journal.pone.0012220.g002
Figure 3. Mast cells do not affect early colitis severity in
Helicobacter-infected Il10
2/2 mice. Both IL-10-deficient and DKO
mice exhibited severe colonic inflammation when infected with H.
rodentium and H. typhlonius for 30 d (n=3 for Ill0
2/2 and n=4 for DKO
mice) compared to Tnf
2/2 and sash mice (n=4 each) (p,0.001 for both
Il10
2/2 and DKO vs. Tnf
2/2 and sash). * indicates p,0.01, comparing
control (non-infected) and infected mice of a given genotype.
doi:10.1371/journal.pone.0012220.g003
Mast Cells and IBD
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presented also show that mast cell-deficient DKO mice are at
increased risk for spontaneous development of IBD compared to
mast cell-sufficient Il10
2/2 mice. These results parallel previous
studies in humans demonstrating that patients with IBD and 10–
25% of their first degree relatives have increased paracellular
permeability relative to controls and that relapse of quiescent IBD
was often preceded by increased intestinal permeability [29,30,31].
Interestingly, the Il10
2/2 mice in our study had low gut
permeability even at the relatively advanced ages of 30–35 wks.
Others have shown that Il10
2/2 mice develop increased gut
permeability prior to development of colitis [32]. However, the
lack of barrier dysfunction in the 30–35 wk old Il10
2/2 mice
reported here (Figure 8) correlates very well with the low incidence
of spontaneous colitis (2 of 15=13%) that we observed in 36 wk
old Il10
2/2 mice (Figure 7).
A recent report by Groschwitz et al [8] showed that jejunal tissue
from mast cell-deficient mice had decreased baseline permeability ex
vivo compared to jejunal tissue from wild type mice. Our data
differs since it represents an integration of the permeability of non-
manipulated tissues throughout the gastrointestinal tract of live
mice. The permeability characteristics of small intestine and colon
are known to be different with respect to water as well as a variety
of nutrients. Our in vivo studies also include potential contributions
from different mast cell subsets that may be present in different
parts of the intestinal tract, bacterial-mucosal interactions,
leukocyte trafficking, and transient inflammation that can also
affect net intestinal permeability in vivo. It is also possible that mast
cells contribute differentially to homeostatic versus inflammation-
induced barrier function. For example, during the normal non-
inflamed state, mast cells may increase permeability (as reported
by Groschwitz et al. [8]) to optimize small intestinal absorption of
nutrients and antigens and to facilitate cellular interaction
important for both digestive and immune system functions.
However, mast cells may limit inflammation-induced barrier
dysfunction by rapidly responding to pathogens that cross the
mucosal barrier. The specific types of mast cells present and the
quantity and type of mediators they release upon activation are
likely to be critical in regulating their net effect [33].
We found that mast cell-sufficient Il10
2/2 mice demonstrated
decreased mucosal production of several pro-inflammatory
cytokines (TNF, IFNc, and IL12/23p40) compared with mice
singly deficient in IL-10, mast cells, or TNF (Figure 4). Several
previous studies using murine models have shown these pro-
inflammatory cytokines can directly increase intestinal epithelial
permeability by inducing disassembly of epithelial cell tight
junctions (reviewed in [1]). Based on current understanding of
tight junction function, the decrease in claudin-3 documented in
Figure 4. Mast cells modulate pro-inflammatory cytokine mRNA expression in inflamed cecal tissues. Cytokine mRNA expression in
cecal tissue of mice of the indicated genotypes harvested after 5 weeks of infection with H. rodentium and H. typhlonius was measured by real-time
PCR, normalized to b-actin and expressed as fold-induction relative to non-infected cecal tissue of the same genotype. Bars represent 5–6 mice per
genotype. * indicates p,0.05 compared to Il10
2/2 mice. Infected DKO mice have increased expression of Th1 cytokines (TNF, IFN-c) and a trend
towards increased Th2 (IL-4) and Th17-inducing cytokines (IL-12/23p40) compared with mast cell-sufficient Il10
2/2 mice.
doi:10.1371/journal.pone.0012220.g004
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expected to increase the in vivo permeability of their intestinal
tissues in vivo [11]. Perturbation of tight junctions and increased
mucosal permeability and activation of the mucosal immune
system have been shown to affect the severity of mucosal
inflammation in humans [34,35,36]. However, since effect of
mast cells on the mucosal barrier likely results from a balance of
multiple effector and immunoregulatory functions [10], more
studies will be required to precisely determine the mechanisms
involved.
The Kit
W-sh allele that renders sash mice mast cell-deficient
contains an inversion that abolishes Kit expression in mast cells and
melanocytes but does not affect Kit expression in most other cell
types [37].Recentwork has further identified that this inversionalso
inhibits the production of corin, a proteinase responsible for the
activation ofatrial natriureticpeptide[38]. It is alsopossible that the
increased permeability may be due to this or to other factors in sash
mice that render them susceptible to inflammation independent of
their mast cell deficiency. However, we note that, despite their
increased intestinal permeability, micebearing the Kit
W-sh mutation
alone do not have added susceptibility to IBD in the absence of
concomitant IL-10 deficiency. Furthermore, reconstitution of
Il10
2/2 mice also homozygous for the Kit
W-sh mutation (DKO)
mice with mast cells does not affect IBD severity (Figures 2 and 3).
Since mast cells protect Il10
2/2 mice from spontaneous IBD,
their failure to influence the severity of inflammation triggered by
exposure of Il10
2/2 mice to piroxicam or co-infection with H.
rodentium and H. typhlonius may seem paradoxical at first glance.
However, this result is predicted by the three factor model of IBD
pathogenesis presented earlier [1]. Il10
2/2 mice have bacteria
within their intestine and their IL-10 deficiency results in defective
immunoregulation. The model thus predicts that colitis will
develop when the mucosal barrier is compromised. Exposure to
piroxicam or infection with helicobacter already compromises
mucosal barrier sufficiently to result in colitis. Thus further
compromise of the barrier by mast cell deficiency would be
predicted to have little to no additional effect, as was observed
experimentally. Additional studies using mice with mast cell
deficiency and/or alterations in intestinal permeability derived via
other mechanisms will be useful for further confirming (or
disproving) this hypothesized mechanism.
We also found that the presence or absence of mast cells had no
effect on the incidence or progression of inflammation-associated
colon cancers in Il10
2/2 mice with colitis. There is currently
controversy in the literature regarding the role of mast cells in
tumor progression in the colon. Mice with a genetic susceptibility
to intestinal neoplasia (Apc
Min) had a greater frequency and size of
adenomas in the absence of mast cells, suggesting a protective
function for mast cells in colorectal carcinogenesis [23]. However,
another report [22] showed recently that mast cells were required
for the growth of adenomatous polyps in mice. Of note, both of
these studies used different strains of mice genetically susceptible to
polyp formation in models with minimal inflammation. Mast cells
may thus have varying effects on the inflammatory milieu in these
models based on any additional environmental triggers of
intestinal inflammation that may be present.
In summary, our studies suggest that mast cells have primarily a
protective role within the colonic microenvironment, serving to
enhance barrier function and limit spontaneous inflammation.
However, the presence of mast cells is insufficient to affect the
severity of IBD triggered by massive disruption of the mucosal
barrier and does not affect the development and progression of
colorectal neoplasia associated with severe IBD.
Materials and Methods
Ethics Statement
All animal studies were approved by the Institutional Animal
Care and Use Committee of Duke University, an institution
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International. The protocol
numbers covering this work were A225-06-07 and A151-09-05.
Animal Studies
Breeding pairs of IL-10-deficient mice (strain name=B6.129P2-
Il10
tm1Cgn/J; stock # 002251), sash mice (strain name=B6.Cg-
Kit
W-sh/HNihrJaeBsmJ; stock #005051), mice transgenic for global
expression of green fluorescent protein (GFP) (strain
name=C57BL/6-Tg(UBC-GFP)30Scha/J; stock # 004353), and
mice deficient in TNF (strain name=B6.129S6-Tnf
tm1Gkl/J; stock
# 005540) were obtained from Jackson Laboratories (Bar Harbor,
ME). IL-10-deficient mice have been documented to be highly
Figure 5. Mast cells do not affect long-term colitis severity in
Helicobacter-infected Il10
2/2 mice. Il10
2/2 mice with (n=21) and
without (n=24) genetic deficiency of mast cells were infected with H.
rodentium and H. typhlonius and monitored for up to 27 wks. DKO mice
had a small increase in histologic score compared with mice deficient in
IL-10 alone (A; p=0.03), but there was no difference in survival between
DKO and mast cell-sufficient Il10
2/2 mice (B).
doi:10.1371/journal.pone.0012220.g005
Mast Cells and IBD
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to triggers such as infection with intestinal helicobacter species or
exposure to NSAIDs that damage their mucosal barrier [4,5,6,39].
The Kit
W-sh allele contains an inversion located proximal to the
Kit locus that abolishes Kit expression in mast cells and
melanocytes but does not affect Kit expression in germ cells or
erythrocytes [37]. Thus, although sash mice are white and lack
mast cells, they can be propagated as homozygotes with normal
litter sizes [40]. Il10
2/2 and sash strains were crossed to generate
DKO mice that were IBD-susceptible and lacked mast cells. All of
these strains were on the C57BL/6 background.
Mice were housed in polycarbonate micro-isolator cages in
individually ventilated racks under BSL-2 conditions, with access
to food and water ad libitum. Mice were observed daily for clinical
signs of distress and weight was monitored three times per week.
Humane endpoints included .15% loss of body weight and
development of rectal prolapse, a well-recognized complication of
chronic inflammation in the colon.
Sentinel mice exposed repetitively to dirty bedding from the
mice used in this study were negative for parasites by microscopic
exam, negative for Citrobacter rodentium by fecal culture, and
negative by serology for a panel of 22 murine protozoal, bacterial,
and viral pathogens, including murine parvovirus, murine
hepatitis virus, and murine norovirus. All mice not intentionally
infected with Helicobacter spp. were confirmed to be Helicobacter-
free by PCR of feces using a species-specific primer.
Models of Inflammatory Bowel Disease
For studies of spontaneous colitis, cohorts of mice were housed
under specific pathogen-free conditions and euthanized for
histologic scoring of colon inflammation if they experienced
.15% loss of body weight, rectal prolapse, or reached pre-
determined time points. Some cohorts of mice were exposed to
200 ppm piroxicam in powdered LabDiet 5001 chow (Purina,
Framingham, MA) for 7 days to trigger the onset of colitis as
previously described [6]. Based on measured food consumption, the
dose of piroxicam averaged 40 mg/kg/day (range 21–62 mg/kg/
day over 35 cage-days). The mice were then placed back on pelleted
5001 chow without piroxicam and observed for an additional 16
days before euthanasia for histologic scoring of colon inflammation.
For studies of colitis triggered by helicobacter infection, 6–8 wk old
mice were infected with H. typhlonius (clinical isolate DU-01) [41]
Figure 6. Colon histology and neoplasia in Helicobacter-infected and non-infected Il10
2/2 and DKO adult mice. Helicobacter-infected
Il10
2/2 (A, B) and DKO mice (C, D) uniformly exhibited mucosal hyperplasia with prominent inflammatory infiltrates. Examples of neoplastic lesions
seen in the long-term study are shown. The arrow in D indicates malignant glands that have invaded into the serosa. Bar represents 1 mm in the
large panels and 100 mm in the insets.
doi:10.1371/journal.pone.0012220.g006
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by gavage of a single dose of 500 ml culture (generally 10
8
organisms) as previously described [6]. Infection was confirmed 7
days post-infection (PI) by quantitative real time PCR of feces (see
below). Similar numbers of helicobacter organisms were present in
feces on day 7 post-infection for Il10
2/2 mice infected with 10
4,
10
6,o r1 0
8 organisms and all infected mice developed severe colitis
(data not shown). Thus the severity of colonic inflammation was
insensitive to inoculum size over the range of 10
4–10
8 helicobacter
organisms due to their rapid in vivo multiplication. Mice were
euthanized by CO2 asphyxiation in accordance with the American
Veterinary Medical Association Recommendations on Euthanasia
if they developed 15% body weight loss, rectal prolapse, or at 25–
36 wks after infection. All mice in this study were evaluated
pathologically for both colitis and neoplasia.
Tissue collection
After euthanasia, the digestive tract from stomach to anus was
removed and divided into segments representing the stomach,
cecum, and proximal, mid-, distal, and terminal colon/rectum.
Portions of each gastrointestinal segment were rinsed briefly with
PBS to remove non-adherent organisms. Tissues for molecular
analysis were immediately frozen and stored at -20uC for
subsequent quantitation of mRNAs or associated Helicobacter
organisms by quantitative real-time PCR. The remaining tissues
were fixed in Carnoy’s solution for 2–4 hrs, then processed and
embedded into paraffin.
Histological Scoring
The severity of colonic inflammation and incidence of colon
neoplasia seen in hematoxylin and eosin-stained sections was
scored by a board-certified pathologist blinded to experimental
group. Histologic scores were calculated as described ([43];
modified from [44]), using a scale that takes into account mucosal
changes in 5 different bowel segments, including hyperplasia and
ulceration, degree of inflammation, and % of each bowel segment
affected by these changes. Using this scale, the maximum score is
75 and a score .12 indicates the presence of colitis.
Neoplastic lesions were classified according to a consensus
report for intestinal neoplasia in mouse models as gastrointestinal
intraepithelial neoplasia or invasive carcinoma [45]. The category
of gastrointestinal intraepithelial neoplasia is synonymous with
atypical hyperplasia, atypia, microadenoma, carcinoma in situ, and
dysplasia, which are non-invasive neoplastic lesions. A diagnosis of
invasive carcinoma required the presence of a desmoplastic
response to differentiate invasion from mucosal herniation or
pseudoinvasion. Regions of neoplasia that were separated by
regions of normal mucosa were scored as separate lesions.
Figure 7. Severity of spontaneous IBD in specific pathogen-
free Il10
2/2 and DKO mice. Il10
2/2 mice on the C57BL/6 background
rarely developed spontaneous colitis by 36 weeks of age when housed
under clean conditions, free from specific pathogens including
Helicobacter spp. (mean histologic scores 6 SEM=1362; n=15). In
contrast, DKO mice that lacked mast cells frequently developed
spontaneous colitis (mean histologic scores=2764; n=10; p=0.02),
which was evident at an earlier age (3162 wks vs. 3661 wks; p=0.02)
compared with Il10
2/2 mice.
doi:10.1371/journal.pone.0012220.g007
Figure 8. Permeability of the intestinal barrier in IL-10
2/2 and
DKO mice. Mice of the indicated ages and genotypes were gavaged
with phenol red and the amount of dye absorbed was determined by
spectrophotometric measurement of urine. Each point shown repre-
sents the average of 2–4 mice tested in a single experiment. Mast cell-
deficient DKO and sash mice had significantly increased dye recovery
compared with Il10
2/2 mice (p=0.02 for differences in data point
elevation via linear regression analysis). The total numbers of mice
tested were: Il10
2/2 (n=14), DKO (n=18), and sash (n=22).
doi:10.1371/journal.pone.0012220.g008
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For detection of helicobacter organisms, DNA was extracted from
40 mg frozen tissue or 20 mg feces using the DNeasy Tissue kit
(Qiagen, Valencia, CA). Real-time PCR was performed to quantify
the relative concentrations of fecal and mucosa-associated H.rodentium
and H. typhlonius organisms per milligram of feces or tissue based on
comparison with a standard, as described previously [6].
For analysis of cytokine expression, total RNA was extracted
from ,30 mg cecal tissue using the RNA extraction kit (Ambion,
Austin, TX). Complementary DNA (cDNA) was synthesized using
1 mg of RNA through a reverse transcription reaction (Applied
Biosystems, Foster City, CA). Real-time PCR quantitative mRNA
analyses were performed using SYBR green fluorescence (Strata-
gene, Cedar Creek, TX). The standard PCR conditions were
95uC for 10 min, 40 cycles for 1 min at 94uC, 56uC for 1 min and
72uC for 2 min, followed by the standard denaturation curve. The
primer sequences used in this analysis were modified from
Cardoso et al. [46] and were as follows: b-actin (fwd, 59-AGT
TGC GTT TTA CAC CCT TT-39; rev, 59-AAG CCA TGC
CAA TGT TGT CT-39), IL-4 (fwd, 59-CTG ACG GCA CAG
AGC TAT TGA-39; rev, 59-TAT GCG AAG CAC CTT GGA
AGC-39), TNF (fwd, 59-TGT GCT CAG AGC TTT CAA CAA-
39; rev, 59-CTT GAT GGT GGT GCA TGA GA-39), IL-12p40
(fwd, 59-AGC ACC AGC TTC TTC ATC AGG-39; rev, 59-GCG
CTG GAT TCG AAC AAA G- 39), IFN-c (fwd,59-GCA TCT
TGG CTT TGC AGC T-39 ; rev, 59-CTT TTT TCG CCT
TGC TGT TG-39). SYBR Green PCR Master Mix (Stratagene,
Cedar Creek, TX), specific primers, and cDNA template were
used in each reaction. The relative mRNA amount of each sample
was calculated based on its threshold cycle, Ct, in comparison to
the Ct of housekeeping gene b-actin. The results for cytokine
mRNAs were demonstrated as mRNA expression relative to non-
infected mice of the same genotype. The purity of amplified
product was determined as a single peak of dissociation curve.
Negative controls without RNA were also performed.
Culture and In vitro Stimulation of Mast Cells
To obtain BMMC, mouse femurs were flushed with RPMI 1640
media using a 22G needle and 10 ml syringe. The bone marrow
cells werecultured for 4 weeks inRPMI1640 (Invitrogen, Carlsbad,
CA) containing 10% fetal bovine serum, essential and non-essential
amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin,
10 mM HEPES, 5.5610
25 M 2-mercaptoethanol, 10 ng/ml stem
cell factor, and 5 ng/ml IL-3 (R&D Systems, Minneapolis, MN) to
stimulate mast cell differentiation. Non-adherent cells were
harvested to flasks containing fresh media once weekly. The
percentage ofmast cellswasdeterminedbyperforming a differential
on a cytocentrifuge preparation stained with a modified Wright-
Giemsa stain; % of mast cells averaged 95%. 10
7 BMMC in 100 ml
PBS were injected intraperitoneally to reconstitute mast cell-
deficient mice, which were used 12 wks after reconstitution.
The in vitro reactivity of BMMC derived from C57BL/6 wild type
or Il10
2/2 mice was compared by measuring degranulation,
viability, and cytokine production post-degranulation. BMMC
(1610
6 cells/well) in Tyrode’s buffer were sensitized by overnight
incubation with 1 mg/ml IgE then stimulated by cross-linking with
1 mg/ml goat anti-mouse IgE (BD, San Jose, CA) or by incubation
with a mixture of enteric bacterial antigens prepared as 100 mg
cecal contents per ml of saline or Tyrode’s buffer then filtered at
0.2 mm. Degranulation was assessed by b-hexoseaminidase activity
using a colorimetric substrate assay as previously described [47].
Viability after degranulation was measured using a tetrazolium-
based colorimetric assay (CellTiter96 Aqueous, Promega, Madison,
WI). Media was harvested from some wells 4 hrs after stimulation
for measurement of cytokine content using a Luminex bead-based
multiplex fluorescent immunoassay (BioRad, Hercules, CA).
Intestinal permeability
The permeability of the mucosal layer was assessed using
phenolsulfonphthalein (phenol red) [48]. Under normal condi-
tions, phenol red is not absorbed in the intestine. However under
conditions of increased intestinal permeability, the dye is absorbed
then excreted in the urine. The urinary dye recovery was
measured after administration of 2 mmol (,700 mg) phenol red
in 0.5 ml of saline by oral gavage. Groups of 2–4 animals were
placed in metabolic caging that is optimized to separate urine from
feces. Urine was collected for 18 hrs, alkalinized extracts were
prepared, and the phenol red content of each sample was
determined spectrophotometrically at 560 nm by comparison to
standards of known concentration. The urinary recovery of phenol
red was expressed as percent of the dose administered.
Statistical Analysis
Statistical comparison of groups was performed using Student’s
t-test. Survival rates were calculated using Kaplan-Meier test with
p-values calculated using the log rank test. Linear regression was
performed using GraphPad prism software. A value of p#0.05 was
considered to be significant.
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